In a recent paper, the authors showed that IDH1/2-mutated AML cells were sensitive to olaparib or talazoparib, and the study further supported the clinical trial of olaparib monotherapy or combined with daunorubicin in AML patients with IDH1/2-mutation (Figure 2) (Molenaar et al., 2018). The gene discussed is IDH1; the disease is acute myeloid leukemia.